title: [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
abstract: A 67-year-old woman was diagnosed as having advanced gastric cancer(poorly differentiated adenocarcinoma)with multiple liver metastases. She had received combined S-1 plus cisplatin chemotherapy as first-line treatment and weekly paclitaxel chemotherapy as second-line treatment, however, both had eventually proved ineffective. Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment. The primary lesion and liver metastatic lesions were confirmed to show remarkable regression. The ToGA trial revealed increased efficacy of trastuzumab in first-line treatment of cancers showing high expression levels of the HER2- protein. This case suggested the increased efficacy of trastuzumab in third-line treatment. Neutropenia and hand foot syndrome of grade 2 were all reported adverse events. She could receive trastuzumab plus XP chemotherapy safely by dose reduction or dormancy temporarily of capecitabine.
authors.affiliation: Division of Gastroenterology, Chigasaki Municipal Hospital.
authors.forename: Yoriko
authors.initials: Y
authors.lastname: Murata
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Matsuura
authors.forename: Kenji
authors.initials: K
authors.lastname: Kanoshima
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kuwabara
authors.forename: Akiko
authors.initials: A
authors.lastname: Fuyuki
authors.forename: Wataru
authors.initials: W
authors.lastname: Tomeno
authors.forename: Reo
authors.initials: R
authors.lastname: Taniguchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kuriyama
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hata
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D060831:Hand-Foot Syndrome; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D016879:Salvage Therapy; D013274:Stomach Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069287:Capecitabine; D002945:Cisplatin; D003841:Deoxycytidine; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab